-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RyMNftIQ277IgSqDnuSRlw5By2KV/GuIcBF2qdzZcbTzvq0BcZy3a6cZTS9/2Cls 0+4Ik6JvLNhfp4z+qPCD8Q== 0000950168-00-000344.txt : 20000216 0000950168-00-000344.hdr.sgml : 20000216 ACCESSION NUMBER: 0000950168-00-000344 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20000215 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SALIX PHARMACEUTICALS LTD CENTRAL INDEX KEY: 0001009356 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943267443 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-53269 FILM NUMBER: 546615 BUSINESS ADDRESS: STREET 1: 3600 W BAYSHORE RD STREET 2: STE 205 CITY: PALO ALTO STATE: CA ZIP: 94303 BUSINESS PHONE: 6508495900 MAIL ADDRESS: STREET 1: 3600 W BAYSHORE BLVD STREET 2: SUITE 205 CITY: PALO ALTO STATE: CA ZIP: 94303 FORMER COMPANY: FORMER CONFORMED NAME: SALIX HOLDINGS LTD DATE OF NAME CHANGE: 19970807 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: CHAPPELL JOHN F CENTRAL INDEX KEY: 0001053880 STANDARD INDUSTRIAL CLASSIFICATION: [] FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 1787 SENTRY PARKWAY WEST STREET 2: BLDG 16 SUITE 360 CITY: BLUE BELL STATE: PA ZIP: 19422 BUSINESS PHONE: 2155422727 MAIL ADDRESS: STREET 1: 1787 SENTRY PARKWAY WEST STREET 2: BLDG 16 SUITE 350 CITY: BLUE BELL STATE: PA ZIP: 19422 SC 13G/A 1 JOHN F. CHAPPELL SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* Salix Pharmaceuticals, Ltd. --------------------------- (Name of Issuer) Common Stock ------------ (Title of Class of Securities) 794906 3 05 ------------------------ (CUSIP Numbers) December 31, 1999 ----------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [ ] Rule 13d-1(c) [X] Rule 13d-1(d) - ------------------------ *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ____________________________________________________________ 1. Name of Reporting Person I.R.S. Identification No. of Above Person John F. Chappell ____________________________________________________________ 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) ____ Not Applicable (b) ____ ____________________________________________________________ 3. SEC Use Only ____________________________________________________________ 4. Citizenship or Place of Organization United States ____________________________________________________________ 5. Sole Voting Power Number of 909,494 Shares ________________________________________ Beneficially 6. Shared Voting Power Owned By Each Reporting Person ________________________________________ 7. Sole Dispositive Power 909,494 ________________________________________ 8. Shared Dispositive Power ____________________________________________________________ 9. Aggregate Amount Beneficially Owned by Each Reporting Person 909,494 ____________________________________________________________ 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) / / ____________________________________________________________ 11. Percent of Class Represented by Amount in Row (9) 8.91% ____________________________________________________________ 12. Type of Reporting Person (See Instructions) IN ____________________________________________________________ ITEM 1(A) NAME OF ISSUER Salix Pharmaceuticals, Ltd. ITEM 1(B) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES 3600 W. Bayshore Road, Suite 205, Palo Alto, CA 94303 ITEM 2(A) NAME OF PERSON FILING John F. Chappell ITEM 2(B) ADDRESS OF PRINCIPAL BUSINESS OFFICE, OR, IF NONE, RESIDENCE 1787 Sentry Parkway West, Bldg. 16, Suite 350, Blue Bell, PA, 19422 ITEM 2(C) CITIZENSHIP United States ITEM 2(D) TITLE OF CLASS OF SECURITIES Common Stock ITEM 2(E) CUSIP NUMBER 794906 3 05 ITEM 3. FILING PURSUANT TO RULES 13D-1(B) OR 13D-2(B) Not Applicable ITEM 4. OWNERSHIP (a) Amount beneficially owned: 909,494 (b) Percent of class: 8.91% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 909,494 (ii) Shared power to vote or to direct the vote: (iii) Sole power to dispose or to direct the disposition of: 909,494 (iv) Shared power to dispose or to direct the disposition of: ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS Not Applicable ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON Not Applicable ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY Not Applicable ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP Not Applicable ITEM 9. NOTICE OF DISSOLUTION OF GROUP Not Applicable ITEM 10. CERTIFICATION Not Applicable After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 14, 2000 - -------------------------------------------- Date /s/ John F. Chappell - -------------------------------------------- John F. Chappell -----END PRIVACY-ENHANCED MESSAGE-----